Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 4Neuroblastoma 2Neoplasms 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Glioblastoma 2Recurrence 1Lymphoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced Cancers 1Advanced Cancer 1Adenocarcinoma 1

Interventions

Fluorouracil 11Gemcitabine 8pembrolizumab 7Leucovorin 7Irinotecan 7Paclitaxel 6Oxaliplatin 5Carboplatin 5130-nm albumin-bound paclitaxel 5Nivolumab 4Cisplatin 4Albumin-Bound Paclitaxel 4Taxes 3Ramucirumab 3Radiosurgery 3Pemetrexed 3Docetaxel 3Capecitabine 3Bevacizumab 3vandetanib 2spartalizumab 2selinexor 2osimertinib 2folfirinox 2Radiation 2Cyclophosphamide 2zolbetuximab 1trastuzumab deruxtecan 1trametinib 1tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenocarcinoma × Crizotinib × Clear all
NCT01579994 2020-12-30

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
13 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡